Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Profound Medical (PROF) Finished Goods (2023 - 2026)

Profound Medical has reported Finished Goods over the past 3 years, most recently at $5.3 million for Q4 2025.

  • For Q4 2025, Finished Goods rose 37.61% year-over-year to $5.3 million; the TTM value through Dec 2025 reached $5.3 million, up 37.61%, while the annual FY2025 figure was $5.3 million, 37.61% up from the prior year.
  • Finished Goods for Q4 2025 was $5.3 million at Profound Medical, down from $5.8 million in the prior quarter.
  • Over five years, Finished Goods peaked at $5.8 million in Q3 2025 and troughed at $3.8 million in Q4 2024.
  • A 3-year average of $5.0 million and a median of $5.0 million in 2023 define the central range for Finished Goods.
  • Biggest five-year swings in Finished Goods: fell 17.27% in 2024 and later surged 37.61% in 2025.
  • Year by year, Finished Goods stood at $4.6 million in 2023, then fell by 17.27% to $3.8 million in 2024, then surged by 37.61% to $5.3 million in 2025.
  • Business Quant data shows Finished Goods for PROF at $5.3 million in Q4 2025, $5.8 million in Q3 2025, and $5.6 million in Q2 2025.